Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393199 | 0.82 | LIPE (0.46) | HTR2AHTR2CLIPEMEN1KMT2A | |
| SCHEMBL4384497 | 0.80 | MEN1 (0.43) | LIPEMEN1KMT2AEPHX2HSD11B1 | |
| SCHEMBL4381887 | 0.78 | HDAC3 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4380733 | 0.78 | EPHX2 (0.47) | HTR2ALIPEMEN1KMT2AEPHX2 | |
| SCHEMBL4390793 | 0.78 | MEN1 (0.45) | LIPEMEN1KMT2AEPHX2 | |
| SCHEMBL4382851 | 0.77 | ALDH1A1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4388046 | 0.76 | SCN9A (0.44) | HTR2AHTR2CLIPESCN9A | |
| SCHEMBL4382729 | 0.76 | EPHX2 (0.50) | LIPEMEN1KMT2AEPHX2EPHX1 | |
| SCHEMBL4383823 | 0.76 | GBA1 (0.46) | LIPEMEN1KMT2AEPHX2HSD11B1 | |
| SCHEMBL4381986 | 0.75 | MEN1 (0.49) | LIPEMEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | HTR2A 956/4885HTR2C 360/4885PSEN1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.